Director Josef von Rickenbach adds 47,060 Rein Therapeutics (RNTX) shares in open-market buys

Rhea-AI Filing Summary

Rein Therapeutics director Josef H. von Rickenbach reported a series of open-market purchases of Rein Therapeutics, Inc. common stock. Between May 21 and May 27, 2026, he bought a total of 47,060 shares at weighted average prices slightly above $1.00 per share.

The individual purchases were 3,420 shares at $1.0422 on May 21, 15,950 shares at $1.0475 on May 22, 23,190 shares at $1.0552 on May 26, and 4,500 shares at $1.0708 on May 27, all as non-derivative common stock transactions. Following these purchases, he directly owns 62,514 shares of Rein Therapeutics common stock.

Insider Trade Summary

Net Buyer: 47,060 shares ($49,561)

Net Buy 4 txns

Insider VON RICKENBACH JOSEF H

Role null

Bought 47,060 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common stock , $0.001 par value	4,500	$1.0708	$5K
Purchase	Common stock , $0.001 par value	23,190	$1.0552	$24K
Purchase	Common stock , $0.001 par value	15,950	$1.0475	$17K
Purchase	Common stock , $0.001 par value	3,420	$1.0422	$4K

Holdings After Transaction: Common stock , $0.001 par value — 62,514 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

May 21 purchase: 3,420 shares at $1.0422 May 22 purchase: 15,950 shares at $1.0475 May 26 purchase: 23,190 shares at $1.0552 +3 more

6 metrics

May 21 purchase 3,420 shares at $1.0422 Open-market common stock purchase on May 21, 2026

May 22 purchase 15,950 shares at $1.0475 Open-market common stock purchase on May 22, 2026

May 26 purchase 23,190 shares at $1.0552 Open-market common stock purchase on May 26, 2026

May 27 purchase 4,500 shares at $1.0708 Open-market common stock purchase on May 27, 2026

Post-transaction holdings 62,514 shares Direct common stock ownership after May 27, 2026 trade

Net buy shares 47,060 shares Net-buy activity summarized across four transactions

Key Terms

open-market purchase, non-derivative, weighted average price, multiple transactions

4 terms

open-market purchase financial

"transaction_action: "open-market purchase" for each common stock transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"transaction_type: "non-derivative" for all reported common stock trades"

weighted average price financial

"The prices reported in Column 4 are a weighted average price for purchase on the respective day."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035..."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VON RICKENBACH JOSEF H

(Last) (First) (Middle)

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TEXAS 78758

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock , $0.001 par value	05/21/2026		P		3,420(1)	A	$1.0422	18,874(1)	D
Common stock , $0.001 par value	05/22/2026		P		15,950(1)	A	$1.0475	34,824(1)	D
Common stock , $0.001 par value	05/26/2026		P		23,190(1)	A	$1.0552	58,014(1)	D
Common stock , $0.001 par value	05/27/2026		P		4,500(1)	A	$1.0708	62,514(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).

	/s/ Josef H. von Rickenbach	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did Rein Therapeutics (RNTX) report for Josef H. von Rickenbach?

Rein Therapeutics reported that director Josef H. von Rickenbach bought common stock in four open-market transactions. These non-derivative purchases occurred between May 21 and May 27, 2026, increasing his directly held position in Rein Therapeutics common shares.

How many Rein Therapeutics (RNTX) shares did Josef H. von Rickenbach purchase?

He purchased a total of 47,060 Rein Therapeutics common shares. The buys were spread across four dates, with individual transactions of 3,420, 15,950, 23,190, and 4,500 shares, all reported as open-market purchases of non-derivative common stock.

At what prices did Josef H. von Rickenbach buy RNTX stock?

The reported weighted average prices per share were $1.0422, $1.0475, $1.0552, and $1.0708. A footnote explains these averages reflect multiple trades within daily price ranges slightly above $1.00 per share during May 21–27, 2026.

What is Josef H. von Rickenbach’s RNTX shareholding after these Form 4 purchases?

After the reported transactions, Josef H. von Rickenbach directly owns 62,514 shares of Rein Therapeutics common stock. This total reflects his position following the final open-market purchase reported on May 27, 2026 in the Form 4 filing.

Were derivatives involved in Josef H. von Rickenbach’s recent RNTX transactions?

No, the reported transactions all involve non-derivative common stock. The Form 4 classifies each as an open-market purchase of common stock, and the derivative holdings summary shows no remaining derivative positions reported in this particular filing.

How many buy and sell transactions did the Rein Therapeutics (RNTX) Form 4 summarize?

The transaction summary lists four buy transactions and zero sales. It shows net-buy activity of 47,060 shares, with no exercises, gifts, tax withholdings, or restructuring-related transfers disclosed in this Form 4 filing.